Effects of oral administration of lauric acid on gut hormone release and appetite perceptions in healthy people

Not Applicable

Completed

• Conditions: Obesity; Type 2 diabetes; Healthy Human Gastrointestinal Physiology; Diet and Nutrition - Obesity; Oral and Gastrointestinal - Normal oral and gastrointestinal development and function; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12619000075189
• Lead Sponsor: Prof. Christine Feinle-Bisset

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-21
• Study Completion: 2019-04-17
• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

Healthy lean (BMI 19-25 kg/m2) male subjects aged between 18 - 55 years, non-smoker, and without significant illness will be included in the study.

Exclusion Criteria

Significant gastrointestinal symptoms, disease or surgery;
Current gallbladder or pancreatic disease;
Cardiovascular or respiratory diseases;
Diagnosed type 2 diabetes;
Any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above);
Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, gastrointestinal function, body weight or appetite (eg domperidone, cisapride, anticholinergic drugs (eg atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.);
Individuals with low ferritin (less than 30 ug/L) or iron (less than 8 umol/L) levels, or who have donated blood in the 12 weeks prior to taking part in the study;
Lactose intolerance/other food allergy(ies);
Vegetarians;
Current intake of greater than 2 standard drinks on greater than 5 days per week;
Current smokers of cigarettes/cigars/marijuana;
Current intake of any illicit substance;
High performance athletes;
Inability to comprehend study protocol;
Restrained eaters (score >12 on the three factor eating questionnaire).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
changes in gut hormones concentrations including cholecystokinin, PYY and ghrelin<br>This outcome is of an exploratory nature so that other gastrointestinal hormones to be measured may be decided upon based on the effect of the intervention on this and other outcomes.[ Plasma will be obtained from blood samples taken at t = -2, 15, 30, 45, 60, 90, 120, 150, and 180 min.]

Secondary Outcome Measures

Name	Time	Method
Measure hunger sensation using a VAS questionnaire[ VAS questionnaires will be completed at t = -2, 15, 30, 45, 60, 90, 120, 150 and 180 min.];Measure fullness sensation using a VAS questionnaire[ VAS questionnaires will be completed at t = -2, 15, 30, 45, 60, 90, 120, 150 and 180 min.];Measure the desire to eat using a VAS questionnaire[ VAS questionnaires will be completed at t = -2, 15, 30, 45, 60, 90, 120, 150 and 180 min.];Measure the amount of food the subject thinks he/she could eat[ VAS questionnaires will be completed at t = -2, 15, 30, 45, 60, 90, 120, 150 and 180 min.]